Skip to main content
. 2015 Aug 11;8(2):75–92. doi: 10.1007/s12307-015-0170-1

Fig. 1.

Fig. 1

The addition of interferon-alpha to pioglitazone in pretreated renal clear cell carcinoma is associated with inflammation control, improved PFS and OS in comparison with a historical control. PFS and OS data compare with those achieved in first-line with standard therapies